WO2008123231A1 - Novel cyclic staple-type oligonucleotide, and nf-κb decoy comprising the same - Google Patents

Novel cyclic staple-type oligonucleotide, and nf-κb decoy comprising the same Download PDF

Info

Publication number
WO2008123231A1
WO2008123231A1 PCT/JP2008/055534 JP2008055534W WO2008123231A1 WO 2008123231 A1 WO2008123231 A1 WO 2008123231A1 JP 2008055534 W JP2008055534 W JP 2008055534W WO 2008123231 A1 WO2008123231 A1 WO 2008123231A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotide
staple
decoy
stem structure
disease
Prior art date
Application number
PCT/JP2008/055534
Other languages
French (fr)
Japanese (ja)
Inventor
Toshihiro Nakajima
Akiko Temma
Naho Suzuki
Original Assignee
Anges Mg, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg, Inc. filed Critical Anges Mg, Inc.
Publication of WO2008123231A1 publication Critical patent/WO2008123231A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)

Abstract

Disclosed is a novel oligonucleotide which is highly capable of binding to NF-κB compared to a conventional oligonucleotide decoy for NF-κB, and is therefore useful as a NF-κB decoy. Also disclosed is use of the oligonucleotide for medical purposes. The oligonucleotide is a cyclic staple-type oligodeoxynucleotide composed of a stem structure and two loop structures attached to both termini of the stem structure, wherein the stem structure comprises a double-strand composed of two chains, and each of the two chains comprises a consensus sequence and a 5'-addition sequence and a 3'-addition sequence each having a specific nucleotide sequence and attached to both termini of the consensus sequence. The cyclic staple-type oligodeoxynucleotide is useful as a prophylactic, ameliorating or therapeutic agent for an ischemic disease, an allergic disease, an inflammatory disease, an autoimmune disease, metastasis/invasion of cancer, or cachexia.
PCT/JP2008/055534 2007-03-26 2008-03-25 Novel cyclic staple-type oligonucleotide, and nf-κb decoy comprising the same WO2008123231A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-078316 2007-03-26
JP2007078316A JP2010130900A (en) 2007-03-26 2007-03-26 NOVEL CYCLIC STAPLE-TYPE OLIGONUCLEOTIDE, AND NF-kappaB DECOY COMPRISING THE SAME

Publications (1)

Publication Number Publication Date
WO2008123231A1 true WO2008123231A1 (en) 2008-10-16

Family

ID=39830724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/055534 WO2008123231A1 (en) 2007-03-26 2008-03-25 Novel cyclic staple-type oligonucleotide, and nf-κb decoy comprising the same

Country Status (2)

Country Link
JP (1) JP2010130900A (en)
WO (1) WO2008123231A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026342A1 (en) * 2002-09-20 2004-04-01 Anges Mg, Inc. AGENT CONTAINING NFκB DECOY FOR PROTECTING GRAFT AGAINST NEOINTIMAL THICKENING
JP2005160464A (en) * 2003-12-02 2005-06-23 Corgentech Inc NF-kappaB OLIGONUCLEOTIDE DECOY MOLECULE
WO2007072909A1 (en) * 2005-12-22 2007-06-28 Anges Mg, Inc. NOVEL OLIGONUCLEOTIDE AND NF-κB DECOY COMPRISING THE SAME

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026342A1 (en) * 2002-09-20 2004-04-01 Anges Mg, Inc. AGENT CONTAINING NFκB DECOY FOR PROTECTING GRAFT AGAINST NEOINTIMAL THICKENING
JP2005160464A (en) * 2003-12-02 2005-06-23 Corgentech Inc NF-kappaB OLIGONUCLEOTIDE DECOY MOLECULE
WO2007072909A1 (en) * 2005-12-22 2007-06-28 Anges Mg, Inc. NOVEL OLIGONUCLEOTIDE AND NF-κB DECOY COMPRISING THE SAME

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHN J.D. ET AL.: "Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia", GENE THER., vol. 9, no. 24, 2002, pages 1682 - 1692, XP002314528 *
HOSOYA T. ET AL.: "Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides", FEBS LETT., vol. 461, no. 3, 1999, pages 136 - 140, XP004260536 *
KUNUGIZA Y. ET AL.: "Inhibitory effect of ribbon-type NF-kappaB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro and in vivo", ARTHRITIS RES. THER., vol. 8, no. 4, 2006, pages R103, XP021020579 *

Also Published As

Publication number Publication date
JP2010130900A (en) 2010-06-17

Similar Documents

Publication Publication Date Title
WO2012031515A3 (en) Low-modification biocompatible high polymer sulfhydryl-modified derivatives, cross-linked material thereof, and uses of said material
WO2006124880A3 (en) Systems and methods to facilitate endoscopic interventions
WO2007127263A3 (en) Therapeutic uses of urolithins
WO2007013059A3 (en) Extending intrabody capsule
WO2008033432A3 (en) Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
EP2567964A3 (en) Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection
WO2009011882A3 (en) Endoscopic implant system and method
EP1613251A4 (en) Devices, systems, and methods to fixate tissue within the regions of body, such as the pharyngeal conduit
EP1691760A4 (en) Devices systems, and methods to fixate tissue within the regions of the body, such as the pharyngeal conduit
WO2007121131A3 (en) Medical devices including shape memory materials
IL200407A (en) Stable digestive enzyme compositions, methods of producing the same and uses thereof
HK1124336A1 (en) Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
WO2007056384A3 (en) Mesh anchoring system
WO2006127883A3 (en) Personal care compositions comprising saccharide-siloxane copolymers
WO2007007173A3 (en) Human anti-madcam antibodies
ZA200708327B (en) Reduction of postoperative pain medication
WO2006081517A3 (en) Embolization using poly-4-hydroxybutyrate particles
EP1929043A4 (en) Genemap of the human genes associated with crohn's disease
EP1883708A4 (en) Genemap of the human genes associated with crohn's disease
EP2097540A4 (en) Genemap of the human genes associated with crohn's disease
EP1771188A4 (en) Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
WO2008016677A3 (en) Preparation and utility of deuterated amphetamines
WO2014022566A3 (en) Synthesis of deuterated ribo nucleosides, n-protected phosphoramidites, and oligonucleotides
WO2007075923A3 (en) Treatment of synucleinopathies
ZA200711116B (en) Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08738829

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08738829

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP